Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 101,700 shares, an increase of 32.4% from the October 15th total of 76,800 shares. Based on an average daily trading volume, of 1,851,000 shares, the days-to-cover ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Down 3.9 %

OTCMKTS:BAYRY traded down $0.22 during midday trading on Thursday, reaching $5.36. The company had a trading volume of 3,506,472 shares, compared to its average volume of 1,362,203. The stock’s fifty day simple moving average is $7.39 and its 200-day simple moving average is $7.42. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a 12-month low of $5.33 and a 12-month high of $11.33. The firm has a market capitalization of $21.06 billion, a price-to-earnings ratio of -20.62 and a beta of 1.10.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). Bayer Aktiengesellschaft had a positive return on equity of 16.46% and a negative net margin of 2.02%. The firm had revenue of $10.96 billion for the quarter. On average, sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One investment analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. According to data from MarketBeat, Bayer Aktiengesellschaft has an average rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.